Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.

Literature DB >> 19775316

Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.

V Chatelet, V Frémeaux-Bacchi, T Lobbedez, M Ficheux, B Hurault de Ligny.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19775316 DOI： 10.1111/j.1600-6143.2009.02817.x

Source DB: PubMed Journal: Am J Transplant ISSN： 1600-6135 Impact factor: 8.086

Keyword Cloud
Cited

× No keyword cloud information.

42 in total

1. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Authors: Elena Bresin; Erica Rurali; Jessica Caprioli; Pilar Sanchez-Corral; Veronique Fremeaux-Bacchi; Santiago Rodriguez de Cordoba; Sheila Pinto; Timothy H J Goodship; Marta Alberti; David Ribes; Elisabetta Valoti; Giuseppe Remuzzi; Marina Noris
Journal: J Am Soc Nephrol Date: 2013-02-21 Impact factor: 10.121

2. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors: Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal: Blood Date: 2015-04-01 Impact factor: 22.113

3. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors: Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal: Clin J Am Soc Nephrol Date: 2010-07-01 Impact factor: 8.237

Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.

1. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

2. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

3. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

4. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.

Review 5. Current treatment of atypical hemolytic uremic syndrome.

6. Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura.

Review 7. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

8. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.

Review 9. Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Review 10. aHUS caused by complement dysregulation: new therapies on the horizon.